ESTRO 2024 - Abstract Book

S1643

Clinical - Lung

ESTRO 2024

1 Hospital Universitario Virgen del Rocío, Radiation Oncology, Sevilla, Spain. 2 Hospital Universitario Ramon y Cajal, Radiation Oncology, Madrid, Spain. 3 Fundación Jiménez Díaz, Radiation Oncology, Madrid, Spain. 4 Hospital Clínico Universitario Lozano Blesa, Radiation Oncology, Zaragoza, Spain. 5 Hospital General Universitario Gregorio Marañón, Radiation Oncology, Madrid, Spain. 6 Hospital UniversitarioGran Canaria Doctor Negrín, Radiation Oncology, Las Palmas de Gran Canaria, Spain. 7 Hospital Santa Creu i Sant Pau, Radiation Oncology, Barcelona, Spain. 8 Hospital Universitario La Paz, Radiation Oncology, Madrid, Spain. 9 Hospital Universitario Virgen Macarena, Radiation Oncology, Sevilla, Spain. 10 Hospital Juan Ramón Jiménez, Radiation Oncology, Huelva, Spain. 11 Complejo Hospitalario de Jaén, Radiation Oncology, Jaén, Spain. 12 Hospital Universitario Torrecárdenas, Radiation Oncology, Almería, Spain. 13 Hospital Universitario de Badajoz, Radiation Oncology, Badajoz, Spain. 14 Hospital Universitario de Torrejón, Radiation Oncology, Madrid, Spain. 15 Complejo Hospitalario Universitario de Orense, Radiation Oncology, Orense, Spain. 16 QuirónSalud, Radiation Oncology, Madrid, Spain. 17 Hospital Rey Juan Carlos, Radiation Oncology, Madrid, Spain. 18 Hospital Clínico Universitario de Valladolid, Radiation Oncology, Valladolid, Spain. 19 Clínica IMQ Zorrotzaurre, Radiation Oncology, Bilbao, Spain. 20 Hospital La Luz, Radiation Oncology, Madrid, Spain. 21 Ruber Internacional, Radiation Oncology, Madrid, Spain. 22 Hospital Meixoeiro,, Radiation Oncology, Vigo, Spain. 23 Hospital Universitario de Navarra, Radiation Oncology, Pamplona, Spain. 24 GenesisCare Hospital San Francisco de Asís and La Milagrosa, Clinical Director, Madrid, Spain. 25 GRUPO ONCOLÓGICO ESPAÑOL DE CÁNCER DE PULMÓN, Radiation Oncology, Madrid, Spain

Purpose/Objective:

Combinations of surgery, radiotherapy, and chemotherapy have been the cornerstone in the treatment of stage III NSCLC (Non-Small Cell Lung Cancer), with a new milestone achieved with the approval of Durvalumab maintenance therapy in the unresectable scenario. Several countries have already published retrospective and population-based studies analyzing their management of stage III NSCLC patients. The results of this studies show there are disparities in adherence to the Chemo radiotherapy + durvalumab regimen in Europe and the United States.

The major challenge when analyzing data from Departments of Radiation Oncology (DRO) in Spain is the absence of a population-based study that provides a comprehensive view of the management of these patients.

This study aims to provide real-world insights that will enable us to compare the reality of NSCLC SIII treated in Spanish DROs with data published in neighboring European Union countries

Material/Methods:

The Lung Cancer Study Group of the Spanish Society of Radiation Oncology (GOECP-SEOR) conducted an observational, retrospective, multicenter study. They collected epidemiological, clinical, and oncological data in an online REDCAP database (Research Electronic Data Capture), ensuring compliance with Spanish ethical and legal requirements. Descriptive statistics are presented as median (interquartile range) or mean ± standard deviation for continuous variables, and absolute or relative frequencies for categorical variables. Survival and disease-free survival were assessed using the Kaplan-Meier method.